Pantoprazole
CLINICAL USE
Gastric acid suppression
DOSE IN NORMAL RENAL FUNCTION
Oral: 20–80 mg in the morningIV: 40–160 mg daily; doses >80 mg in 2 divided doses
PHARMACOKINETICS
Molecular weight                           :383.4 %Protein binding                           :98 %Excreted unchanged in urine     : 80 (as metabolites) Volume of distribution (L/kg)       :0.15half-life – normal/ESRD (hrs)      :1/2–3 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal functionCAV/VVHD      :Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Antifungals: absorption of itraconazole and ketoconazole reduced ADMINISTRATION
Reconstition
10 mL sodium chloride 0.9% Route
Oral, IV Rate of Administration
2–15 minutes Comments
Use within 12 hours of reconstitution Dilute to 100 mL with sodium chloride 0.9% or glucose 5%.(15.4 mg/mL) 1 mL contains 10 mg anhydrous morphine, 1.2 mg papaverine HCl, and 1.04 mg codeine HCl
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home